Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Creighton University
The purpose of this project is to determine if eplerenone, an aldosterone blocker, prevents remodelling of the heart in patients with controlled essential hypertension, defined as having a blood pressure of equal to or less than 130/80 in diabetics and equal to or less than 140/90 in non-diabetics. This study will investigate if the addition of 25 milligrams of eplerenone daily to a subject's hypertension medication regimen will prevent the progression or development of diastolic dysfunction. Echocardiography will be used to measure the changes in heart structure of subjects receiving eplerenone versus subjects receiving placebo (a drug that may resemble the study drug but contains no active ingredient). Approximately 30 subjects will take part in this study.
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Treated and controlled hypertension
Less than 140/90 in non-diabetics
Less than 130/80 in diabetics
You may not be if
currently receiving an aldosterone blocker
clinical evidence of congestive heart failure
prior myocardial infarction
renal dysfunction with a creatinine clearance of less than 40ml/min
serum potassium \> 5.5meq/L at initiation
concomitant use of a medication that inhibits the CYP3A4 enzyme (ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir)